Moore Capital Management LP Makes New $8.08 Million Investment in Boston Scientific Corporation $BSX

Moore Capital Management LP bought a new stake in Boston Scientific Corporation (NYSE:BSX) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 189,256 shares of the medical equipment provider’s stock, valued at approximately $8,077,000.

A number of other hedge funds and other institutional investors have also modified their holdings of BSX. Sigma Planning Corp raised its holdings in shares of Boston Scientific by 15.9% during the 2nd quarter. Sigma Planning Corp now owns 8,759 shares of the medical equipment provider’s stock worth $374,000 after acquiring an additional 1,199 shares during the period. Two Sigma Securities LLC increased its position in Boston Scientific by 261.3% during the second quarter. Two Sigma Securities LLC now owns 98,200 shares of the medical equipment provider’s stock worth $4,191,000 after purchasing an additional 71,019 shares during the last quarter. Benjamin Edwards Inc. raised its stake in Boston Scientific by 5.0% during the second quarter. Benjamin Edwards Inc. now owns 47,458 shares of the medical equipment provider’s stock worth $2,025,000 after purchasing an additional 2,263 shares during the period. Wedbush Securities Inc. boosted its holdings in Boston Scientific by 16.8% in the 2nd quarter. Wedbush Securities Inc. now owns 10,620 shares of the medical equipment provider’s stock valued at $453,000 after purchasing an additional 1,530 shares during the last quarter. Finally, Cullinan Associates Inc. boosted its holdings in Boston Scientific by 2.1% in the 2nd quarter. Cullinan Associates Inc. now owns 24,299 shares of the medical equipment provider’s stock valued at $1,037,000 after purchasing an additional 500 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Stifel Nicolaus set a $60.00 price target on shares of Boston Scientific in a report on Wednesday, July 29th. Leerink Partners set a $60.00 price objective on Boston Scientific in a research report on Thursday, July 30th. UBS Group cut their price objective on Boston Scientific from $74.00 to $67.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Raymond James Financial reiterated an “outperform” rating and issued a $57.00 target price on shares of Boston Scientific in a report on Thursday, July 30th. Finally, Bank of America dropped their target price on Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Twenty-four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $71.62.

Insider Buying and Selling at Boston Scientific

In other news, Director David C. Habiger acquired 2,100 shares of Boston Scientific stock in a transaction dated Wednesday, August 5th. The shares were acquired at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the acquisition, the director owned 17,160 shares of the company’s stock, valued at $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Edward J. Ludwig acquired 5,000 shares of the firm’s stock in a transaction dated Friday, July 31st. The shares were purchased at an average cost of $45.48 per share, with a total value of $227,400.00. Following the completion of the transaction, the director owned 30,359 shares in the company, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have bought 194,522 shares of company stock valued at $9,385,210. Insiders own 0.34% of the company’s stock.

Boston Scientific Stock Performance

Shares of BSX opened at $46.82 on Monday. Boston Scientific Corporation has a 1 year low of $42.20 and a 1 year high of $109.50. The stock has a market capitalization of $67.85 billion, a PE ratio of 18.96, a PEG ratio of 1.02 and a beta of 0.56. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The stock has a 50-day simple moving average of $46.56 and a 200-day simple moving average of $56.53.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The firm had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, analysts predict that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific announced that its board has authorized a stock repurchase program on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.